PUBLISHER: KBV Research | PRODUCT CODE: 1309445
PUBLISHER: KBV Research | PRODUCT CODE: 1309445
Europe Fibromyalgia Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Anticonvulsants, Antidepressants, Muscle Relaxants and Others), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030
The Europe Fibromyalgia Treatment Market would witness market growth of 4.0% CAGR during the forecast period (2023-2030).
Fibromyalgia is now more well-known and diagnosed, which has increased the number of patients seeking therapy. More people are expected to receive the correct diagnosis and therapy for their fibromyalgia symptoms as the public and professional understanding of the disorder increases. The disease's rising prevalence and awareness influence the market share.
The market is expanding partly because generic drugs for treating fibromyalgia are now easier to obtain. Numerous advantages that have a positive market impact come from the availability of generic versions of drugs licensed for treating fibromyalgia. When compared to their branded counterparts, generic drugs are less expensive. This accessibility is enhanced by this affordability, especially for people with limited budgets or without complete insurance coverage, which promotes market expansion.
On the contrary, medical professionals and pharmaceutical firms are looking into and creating fresh fibromyalgia therapy choices. These include drugs that treat the condition's underlying causes and symptoms specifically. Thus, the availability of novel treatments gives patients and healthcare professionals more options for therapy, which is expected to fuel the market throughout the forecast period.
Fibromyalgia can be challenging to diagnose, which is one of the primary reasons it is unclear how many people are afflicted. There is no specific diagnostic test for the condition, and the symptoms may resemble those of several other conditions. In Italy, fibromyalgia (FM), the most common cause of widespread musculoskeletal pain, is estimated to afflict 2% of the Italian general population. However, it is not a uniform clinical entity, and several interacting factors can impact patient prognosis and the outcomes of standard treatment programs. Hence, a significant presence of fibromyalgia in the general population is expected to increase the demand for treatment options and propel market growth in Europe.
The Germany market dominated the Europe Fibromyalgia Treatment Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $267 million by 2030. The UK market is anticipated to grow at a CAGR of 3.1% during (2023 - 2030). Additionally, The France market would showcase a CAGR of 4.7% during (2023 - 2030).
Based on Drug Class, the market is segmented into Anticonvulsants, Antidepressants, Muscle Relaxants and Others. Based on Distribution Channel, the market is segmented into Drug stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.
Scope of the Study
Market Segments covered in the Report:
By Drug Class
- Anticonvulsants
- Antidepressants
- Muscle Relaxants
- Others
By Distribution Channel
- Drug stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- AbbVie, Inc.
- Novartis AG
- Eli Lilly And Company
- Amneal Pharmaceuticals, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Zydus Lifesciences Ltd.
- Lupin Limited
- Abbott Laboratories
- Viatris, Inc.
- Sun Pharmaceutical Industries Ltd.
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Fibromyalgia Treatment Market, by Drug Class
- 1.4.2 Europe Fibromyalgia Treatment Market, by Distribution Channel
- 1.4.3 Europe Fibromyalgia Treatment Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market composition & scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. Europe Fibromyalgia Treatment Market by Drug Class
- 3.1 Europe Anticonvulsants Market by Country
- 3.2 Europe Antidepressants Market by Country
- 3.3 Europe Muscle Relaxants Market by Country
- 3.4 Europe Others Market by Country
Chapter 4. Europe Fibromyalgia Treatment Market by Distribution Channel
- 4.1 Europe Drug stores & Retail Pharmacies Market by Country
- 4.2 Europe Hospital Pharmacies Market by Country
- 4.3 Europe Online Providers Market by Country
Chapter 5. Europe Fibromyalgia Treatment Market by Country
- 5.1 Germany Fibromyalgia Treatment Market
- 5.1.1 Germany Fibromyalgia Treatment Market by Drug Class
- 5.1.2 Germany Fibromyalgia Treatment Market by Distribution Channel
- 5.2 UK Fibromyalgia Treatment Market
- 5.2.1 UK Fibromyalgia Treatment Market by Drug Class
- 5.2.2 UK Fibromyalgia Treatment Market by Distribution Channel
- 5.3 France Fibromyalgia Treatment Market
- 5.3.1 France Fibromyalgia Treatment Market by Drug Class
- 5.3.2 France Fibromyalgia Treatment Market by Distribution Channel
- 5.4 Russia Fibromyalgia Treatment Market
- 5.4.1 Russia Fibromyalgia Treatment Market by Drug Class
- 5.4.2 Russia Fibromyalgia Treatment Market by Distribution Channel
- 5.5 Spain Fibromyalgia Treatment Market
- 5.5.1 Spain Fibromyalgia Treatment Market by Drug Class
- 5.5.2 Spain Fibromyalgia Treatment Market by Distribution Channel
- 5.6 Italy Fibromyalgia Treatment Market
- 5.6.1 Italy Fibromyalgia Treatment Market by Drug Class
- 5.6.2 Italy Fibromyalgia Treatment Market by Distribution Channel
- 5.7 Rest of Europe Fibromyalgia Treatment Market
- 5.7.1 Rest of Europe Fibromyalgia Treatment Market by Drug Class
- 5.7.2 Rest of Europe Fibromyalgia Treatment Market by Distribution Channel
Chapter 6. Company Profiles
- 6.1 Abbott Laboratories
- 6.1.1 Company Overview
- 6.1.2 Financial Analysis
- 6.1.3 Segmental and Regional Analysis
- 6.1.4 Research & Development Expense
- 6.1.5 SWOT Analysis
- 6.2 AbbVie, Inc.
- 6.2.1 Company Overview
- 6.2.2 Financial Analysis
- 6.2.3 Regional Analysis
- 6.2.4 Research & Development Expense
- 6.2.5 Recent strategies and developments:
- 6.2.5.1 Acquisition and Mergers:
- 6.3 Novartis AG
- 6.3.1 Company Overview
- 6.3.2 Financial Analysis
- 6.3.3 Segmental and Regional Analysis
- 6.3.4 Research & Development Expense
- 6.3.5 Recent strategies and developments:
- 6.3.5.1 Acquisition and Mergers:
- 6.4 Eli Lilly And Company
- 6.4.1 Company Overview
- 6.4.2 Financial Analysis
- 6.4.3 Regional Analysis
- 6.4.4 Research & Development Expenses
- 6.5 Amneal Pharmaceuticals, Inc.
- 6.5.1 Company Overview
- 6.5.2 Financial Analysis
- 6.5.3 Segmental Analysis
- 6.5.4 Research & Development Expenses
- 6.6 Teva Pharmaceutical Industries Ltd.
- 6.6.1 Company Overview
- 6.6.2 Financial Analysis
- 6.6.3 Regional Analysis
- 6.6.4 Research & Development Expenses
- 6.7 Zydus Lifesciences Ltd.
- 6.7.1 Company Overview
- 6.7.2 Financial Analysis
- 6.7.3 Segmental and Regional Analysis
- 6.7.4 Research & Development Expense
- 6.7.5 Recent strategies and developments:
- 6.7.5.1 Trials and Approvals:
- 6.8 Lupin Limited
- 6.8.1 Company Overview
- 6.8.2 Financial Analysis
- 6.8.3 Recent strategies and developments:
- 6.8.3.1 Trials and Approvals:
- 6.9 Viatris, Inc.
- 6.9.1 Company Overview
- 6.9.2 Financial Analysis
- 6.9.3 Segmental Analysis
- 6.9.4 Research & Development Expense
- 6.10. Sun Pharmaceutical Industries Ltd.
- 6.10.1 Company Overview
- 6.10.2 Financial Analysis
- 6.10.3 Regional Analysis
- 6.10.4 Research & Development Expenses
LIST OF TABLES
- TABLE 1 Europe Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 2 Europe Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 3 Europe Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 4 Europe Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 5 Europe Anticonvulsants Market by Country, 2019 - 2022, USD Million
- TABLE 6 Europe Anticonvulsants Market by Country, 2023 - 2030, USD Million
- TABLE 7 Europe Antidepressants Market by Country, 2019 - 2022, USD Million
- TABLE 8 Europe Antidepressants Market by Country, 2023 - 2030, USD Million
- TABLE 9 Europe Muscle Relaxants Market by Country, 2019 - 2022, USD Million
- TABLE 10 Europe Muscle Relaxants Market by Country, 2023 - 2030, USD Million
- TABLE 11 Europe Others Market by Country, 2019 - 2022, USD Million
- TABLE 12 Europe Others Market by Country, 2023 - 2030, USD Million
- TABLE 13 Europe Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 14 Europe Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 15 Europe Drug stores & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 16 Europe Drug stores & Retail Pharmacies Market by Country, 2023 - 2030, USD Million
- TABLE 17 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 18 Europe Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
- TABLE 19 Europe Online Providers Market by Country, 2019 - 2022, USD Million
- TABLE 20 Europe Online Providers Market by Country, 2023 - 2030, USD Million
- TABLE 21 Europe Fibromyalgia Treatment Market by Country, 2019 - 2022, USD Million
- TABLE 22 Europe Fibromyalgia Treatment Market by Country, 2023 - 2030, USD Million
- TABLE 23 Germany Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 24 Germany Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 25 Germany Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 26 Germany Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 27 Germany Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 28 Germany Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 29 UK Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 30 UK Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 31 UK Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 32 UK Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 33 UK Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 34 UK Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 35 France Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 36 France Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 37 France Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 38 France Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 39 France Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 40 France Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 41 Russia Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 42 Russia Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 43 Russia Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 44 Russia Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 45 Russia Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 46 Russia Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 47 Spain Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 48 Spain Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 49 Spain Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 50 Spain Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 51 Spain Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 52 Spain Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 53 Italy Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 54 Italy Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 55 Italy Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 56 Italy Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 57 Italy Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 58 Italy Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 59 Rest of Europe Fibromyalgia Treatment Market, 2019 - 2022, USD Million
- TABLE 60 Rest of Europe Fibromyalgia Treatment Market, 2023 - 2030, USD Million
- TABLE 61 Rest of Europe Fibromyalgia Treatment Market by Drug Class, 2019 - 2022, USD Million
- TABLE 62 Rest of Europe Fibromyalgia Treatment Market by Drug Class, 2023 - 2030, USD Million
- TABLE 63 Rest of Europe Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 64 Rest of Europe Fibromyalgia Treatment Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 65 Key Information - Abbott Laboratories
- TABLE 66 Key information - AbbVie, Inc.
- TABLE 67 Key Information - Novartis AG
- TABLE 68 Key Information - Eli Lilly And Company
- TABLE 69 Key Information - Amneal Pharmaceuticals, INc.
- TABLE 70 Key Information - Teva Pharmaceuticals Industries Ltd.
- TABLE 71 Key Information - Zydus Lifesciences Ltd.
- TABLE 72 Key Information - Lupin Limited
- TABLE 73 key information - Viatris, Inc.
- TABLE 74 Key Information - Sun Pharmaceutical Industries Ltd.
List of Figures
- FIG 1 Methodology for the research
- FIG 2 Europe Fibromyalgia Treatment Market share by Drug Class, 2022
- FIG 3 Europe Fibromyalgia Treatment Market share by Drug Class, 2030
- FIG 4 Europe Fibromyalgia Treatment Market by Drug Class, 2019 - 2030, USD Million
- FIG 5 Europe Fibromyalgia Treatment Market share by Distribution Channel, 2022
- FIG 6 Europe Fibromyalgia Treatment Market share by Distribution Channel, 2030
- FIG 7 Europe Fibromyalgia Treatment Market by Distribution Channel, 2019 - 2030, USD Million
- FIG 8 Europe Fibromyalgia Treatment Market share by Country, 2022
- FIG 9 Europe Fibromyalgia Treatment Market share by Country, 2030
- FIG 10 Europe Fibromyalgia Treatment Market by Country, 2019 - 2030, USD Million
- FIG 11 Swot analysis: Abbott laboratories
